# EDGAR Filing Document

**Accession Number:** 0001001233
**File Stem:** 0001628280-23-006092
**Filing Date:** 2023-3
**Character Count:** 8318
**Document Hash:** 859ee5d65f2091b6556d58a773f38943
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-006092.hdr.sgml**: 20230302

**ACCESSION NUMBER**: 0001628280-23-006092

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230302

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20230302

**DATE AS OF CHANGE**: 20230302

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SANGAMO THERAPEUTICS, INC
- **CENTRAL INDEX KEY:** 0001001233
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 680359556
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30171
- **FILM NUMBER:** 23700154

**BUSINESS ADDRESS:**
- **STREET 1:** 7000 MARINA BLVD
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005
- **BUSINESS PHONE:** 5109706000

**MAIL ADDRESS:**
- **STREET 1:** 7000 MARINA BLVD
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SANGAMO BIOSCIENCES INC
- **DATE OF NAME CHANGE:** 20000208

?xml version="1.0" ? sgmo-20230302

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 2, 2023**

**SANGAMO THERAPEUTICS, INC.** 

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-30171** | **68-0359556** |
| **(State or other jurisdiction of<br>incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>ID Number)** |

---

**7000 Marina Blvd., Brisbane, California 94005** 

**(Address of principal executive offices) (Zip Code)**

**(510) 970-6000** 

**(Registrant's telephone number, including area code)** 

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, $0.01 par value per share** | **SGMO** | **Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure.**

Sangamo Therapeutics, Inc. ("Sangamo") today announced that it had recently engaged in discussions with various investors to explore a potential public offering of its securities. After evaluating market conditions as well as ongoing business development discussions and financing opportunities, its cash position and business outlook, Sangamo has chosen not to move forward with a public offering of its securities at this time. As previously disclosed in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2022 (the "Form 10-K"), Sangamo believes that its available cash, cash equivalents, and marketable securities will be adequate to fund its operations for at least 12 months from the date of its consolidated financial statements included in the Form 10-K. Sangamo will continue to evaluate evolving market conditions, its cash needs and business outlook and will continue to seek additional capital, including through non-dilutive sources, and may seek additional equity financing in the future.

The information contained in this Item 7.01 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission (the "SEC") made by Sangamo whether made before or after the date hereof, regardless of any general incorporation language in such filing.

*Forward-Looking Statements* 

*This Current Report on Form 8-K contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, statements relating to the adequacy of Sangamo's cash, cash equivalents and marketable securities to fund its planned operations and the timing thereof. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Sangamo's actual results may differ materially and adversely from those expressed in these forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to: Sangamo's cash position, including the risk that Sangamo's future viability beyond one year from the date of issuance of its consolidated financial statements included in the Form 10-K is dependent on its ability to raise substantial additional capital to finance its operations; Sangamo's ability to effectuate plans to address its liquidity needs, including cost-preservation measures, and to continue as a going concern; Sangamo's ability to raise additional capital on acceptable terms or at all; the uncertain timing and unpredictable nature of clinical trials and clinical trial results; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the effects of the COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and its collaborators, including Sangamo's ability to raise additional capital; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; the manufacturing of products and product candidates; the commercialization of approved products; the potential for technological developments that obviate technologies used by Sangamo; Sangamo's lack of resources to fully develop, obtain regulatory approval for and commercialize its product candidates; and other risks and uncertainties described in Sangamo's filings with the SEC, including in the Form 10-K, and future filings and reports that Sangamo makes from time to time with the SEC. The information contained in this Current Report on Form 8-K is as of March 2, 2023, and Sangamo undertakes no duty to update forward-looking statements contained in this Current Report on Form 8-K except as required by applicable laws.*

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **SANGAMO THERAPEUTICS, INC.** | **SANGAMO THERAPEUTICS, INC.** |
| Dated: March 2, 2023 | By: | /s/ SCOTT B. WILLOUGHBY |
|  | Name: | Scott B. Willoughby |
|  | Title: | Senior Vice President, General Counsel and Corporate Secretary |

---